Cascadian Therapeutics, Inc. - 10-K filing on 2015-03-10

Note 3 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

		December 31, 2014																December 31, 2013
		Level 1				Level 2				Level 3				Total				Level 1				Level 2				Level 3				Total
		(In thousands)
Financial Assets:
Money market funds		$	4,103			$	—			$	—			$	4,103			$	6,058			$	—			$	—			$	6,058
Debt securities of U.S. government agencies			—				43,844				—				43,844				—				49,890				—				49,890
Corporate bonds			—				9,416				—				9,416				—				13,393				—				13,393
		$	4,103			$	53,260			$	—			$	57,363			$	6,058			$	63,283			$	—			$	69,341
Financial Liability:
Restricted Share Units		$	310			$	—			$	—			$	310			$	337			$	—			$	—			$	337
Warrants			—				—				128				128				—				—				924				924

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

		As of December 31, 2014
		September 2010 Warrants
Exercise price		$	4.24
Market value of stock at end of period		$	1.90
Expected dividend rate			0.0	%
Expected volatility			60.3	%
Risk-free interest rate			0.2	%
Expected life (in years)			0.78

		As of December 31, 2013
		May 2009 Warrants				September 2010 Warrants
Exercise price		$	3.74			$	4.24
Market value of stock at end of period		$	1.76			$	1.76
Expected dividend rate			0.0	%			0.0	%
Expected volatility			45.3	%			77.4	%
Risk-free interest rate			0.1	%			0.3	%
Expected life (in years)			0.40				1.78

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

		Years Ended December 31,
		2014				2013
		(In thousands)
Balance at beginning of period		$	924			$	3,251
Change in fair value of warrant liability included in
Other expense (income)			(796	)			(2,327	)
Balance at the end of period		$	128			$	924